Results 181 to 190 of about 69,426 (314)

Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology. [PDF]

NPJ Digit Med
Li L, Jing S, Zhao X, Zhu X, Liang C, Shi L, Zhou P, Xie K, Jin B, Zhu H, Wang Y, Jin X, Du L, Yang P.   +13 more
europepmc   +1 more source

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study [PDF]

B. Y. C. Wan, Zhi Zhou, Ning Ma, Weiying Lu   +3 more
openalex   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase. [PDF]

Fundam Clin Pharmacol
Duboëlle M, Lercara A, Pers YM, Michel C, Lepelley M, Valnet-Rabier MB, Faillie JL, Bres V, Palassin P.   +8 more
europepmc   +1 more source

Risk factors for Enasidenib in the treatment of Acute Myelogenous Leukemia and subgroups analysis: pharmacovigilance of the FDA adverse event reporting system (FAERS) [PDF]

XIE JIANGCHUAN, Qian Gao, Yu Qin, Li Xie, Yongchuan Chen   +4 more
openalex   +1 more source

Teprotumumab-Associated Deafness: A Pharmacovigilance Analysis

, 2023
Mohini Bindal
openalex   +1 more source

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Maliha Malik, Hammad Amjad, Khadija Malik, Muddassir Syed Saleem, Shanzay Akhtar, Muslehuddin Paracha, Mobeen Abid, Nabahat Shafi, Ahmed Asad Raza, Abedin Samadi, Samar Abbas Jaffri   +10 more
wiley   +1 more source

Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review. [PDF]

Ann Hematol
Bisiou S, Lobbes H, Palassin P, Allouchery M, Comont T, Rivet V.   +5 more
europepmc   +1 more source

AI-Driven Signal Detection in Pharmacovigilance: Advancements, Challenges, and Future Directions

Anjali R Chavhan, P.M. Uplenchwar
openalex   +1 more source

Évaluation de l’association entre bisphosphonates et troubles cardiovasculaires : une analyse de disproportionalité sur la base de pharmacovigilance de l’OMS

, 2022
Cortes, Benjamin
openalex   +1 more source